Ezetimibe/rosuvastatin

Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a cholesterol lowering combination medication.[5] In some countries it is sold as a kit or a pack containing two distinct pills.[6][1] It is also available in the form of a composite package containing the two separate pills.[3]

Ezetimibe/rosuvastatin
Combination of
EzetimibeHypolipidemic agent
RosuvastatinStatin
Clinical data
Trade namesRidutrin, Lipocomb, Rosuzet, others[1][2]
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only) [3]
  • US: ℞-only [4]
  • EU: Rx-only [2]
  • In general: ℞ (Prescription only)
Identifiers
KEGG

The combination was approved for medical use in the United States in March 2021.[4]

Medical uses

Ezetimibe/rosuvastatin is indicated as an adjunct to diet in people with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); and alone or as an adjunct to other LDL-C-lowering therapies in people with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.[7]

References
  1. "Rosuvastatin international". Drugs.com. 3 February 2020. Retrieved 17 February 2020.
  2. "Ezetimibe/rosuvastatin: List of nationally authorised medicinal products" (PDF). European Medicines Agency (EMA). 21 March 2018. PSUSA/00010271/201707. Retrieved 17 February 2020.
  3. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2013-PI-02443-1
  4. "Roszet: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 24 March 2021.
  5. "Ridutrin SmPC" (PDF). Medicines Data Bank. 30 May 2019. Retrieved 17 February 2020.
  6. "Rosuzet Composite Pack". NPS MedicineWise. 8 January 2020. Retrieved 17 February 2020.
  7. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/213072Orig1s000ltr.pdf


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.